產(chǎn)品搜索
相關(guān)文章
- 耳聾基因檢測(cè)標(biāo)準(zhǔn)品
- 老靶點(diǎn)迭代突破創(chuàng)新:Her2靶點(diǎn)細(xì)胞模型
- 潛力十足的T細(xì)胞療法,我們用得起嗎?
- GLP-1R、GCGR、GIPR多靶點(diǎn)激動(dòng)劑與代謝疾病
- ATCC細(xì)胞的培養(yǎng)方法
- 近期淋巴癌重磅級(jí)研究一覽
- 4-1BB(CD137)靶點(diǎn)藥物篩選模型
- 新型冠狀病毒:用于診斷的假病毒標(biāo)準(zhǔn)品和用于藥物研發(fā)的假病毒模型
- 腫瘤細(xì)胞調(diào)控關(guān)鍵因子和機(jī)制的研究講解
- 基于納米顆粒的組合免疫療法對(duì)致命性癌癥發(fā)起三重打擊
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73302BCR-ABL1 E459K/BaF3

- 詳細(xì)內(nèi)容
CBP73302 | |
I. Introduction | |
Cell Line Name: | BCR-ABL1 [E459K]/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. | |
III. Representative Data | |
1.WB of BCR-ABL1 [E459K]/BaF3 | |
2.Sanger of BCR-ABL1 [E459K]/BaF3 Figure 2. BCR-ABL1 [E459K]/BaF3 E549K
Figure 3. BCR-ABL1 [E459K]/BaF3 Fusion | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 E459K Cells (C8). | |